DIAGNOS Appoints New Director-Dr. Netan Choudhry

BROSSARD, QUEBEC--(Marketwired - Nov. 29, 2016) - (TSX VENTURE:ADK) - Diagnos Inc. ("Diagnos" or "the Company") a leader in the use of artificial intelligence and advanced knowledge extraction techniques is pleased to announce the appointment of Dr. Netan Choudhry to the board of directors.

Dr. Choudhry is an internationally recognized Vitreorenal Surgeon with affiliations at both the University of Toronto and Harvard Medical School. He is universally recognized as a thought leader in retinal imaging and the diagnosis and treatment of rare disorders of the retina and vitreous.

Dr. Choudhry was the first to pioneer OCT imaging of the peripheral retina and is actively developing novel devices for imaging the retina and vitreous using non-invasive technology. He has published in the world's most read/indexed journals including: The New England Journal of Medicine, the Lancet, Ophthalmology and the Retina Journal. Dr. Choudhry's innovative work in the field of retina has also been published on the covers of numerous journals further earning him the distinction of a pioneer in retinal imaging.

Dr. Choudhry is actively involved in medical education at the University of Toronto Department of Ophthalmology & Visual Sciences and he is also a faculty member for the Massachusetts Eye & Ear Infirmary Harvard Medical School Annual Vitreoretinal Surgery Fellows course. Dr. Choudhry has been an invited speaker at over 75 international conferences and symposia. He has published several book chapters in retinal medicine and wide-field imaging. Dr. Choudhry has also received research grants to investigate: Diabetic retinopathy, Age-Related Macular Degeneration, Macular holes/puckers and uncommon conditions such as Retinitis Pigmentosa and Macular telegiectasia.

"On behalf of my fellow board members, I would like to welcome Dr. Choudhry in joining the board. I am convinced that Diagnos will greatly benefit from Dr. Choudhry broad experience in the eye care sector," said Mr. Philip Renaud, Chairman of the board of directors of Diagnos.

About Diagnos

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.